Searchable abstracts of presentations at key conferences in endocrinology

ea0044p97 | Diabetes and Cardiovascular | SFEBES2016

SGLT2 inhibitors: results from clinical practice

Border Daniel K. , Barber Thomas M.

Introduction: There is growing real-world experience of the SGLT2 inhibitor class for type 2 diabetes mellitus (T2D). We performed an audit of clinico-biochemical effects of SGLT2 inhibitor use for patients with diabesity in the context of a tier-3 obesity service within a UK-based teaching hospital.Methods: We included patients with a confirmed diagnosis of T2D who had been treated with an SGLT2 inhibitor within licensed indications (monotherapy and add...

ea0044p178 | Obesity and Metabolism | SFEBES2016

Dramatic weight loss induced by dapagliflozin and tier 3 obesity service support

Border Daniel K , Barber Thomas M

The importance of weight reduction in the management of diabesity is well-established. However, significant weight loss can be difficult to achieve without bariatric surgery, even within specialist tier 3 obesity services. Here we describe the case of a 52 year old man who presented to weight management clinic. He had made multiple weight loss attempts, but with little success. On presentation, his weight was 140.8 kg with a BMI of 40.3 kg/m2, and he had now been static at thi...

ea0050ep054 | Diabetes and Cardiovascular | SFEBES2017

Significant improvement in response to the GLP1-agonist 'Liraglutide' following change in injection site

Border Daniel , Clayton Wendy , Barber Tom , Randeva Harpal

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...

ea0050ep054 | Diabetes and Cardiovascular | SFEBES2017

Significant improvement in response to the GLP1-agonist 'Liraglutide' following change in injection site

Border Daniel , Clayton Wendy , Barber Tom , Randeva Harpal

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...

ea0034p152 | Clinical practice/governance and case reports | SFEBES2014

Cushing's disease with hepatic adrenal rests

Border Daniel , Aftab Saboor , Pelluri Lavanya , Barber Thomas , Randeva Harpal

We present the case of a 58-year-old woman who presented 30 years ago. She was noted to have abdominal obesity, moon-face and skin bruising/thinning, as well as hypertension. Serum cortisol was elevated and she was presumed to have CushingÂ’s disease (although we have no record of dynamic tests or imaging from the time of her original presentation). Owing to her desire for future fertility, she underwent bilateral adrenalectomy at the age of 31 years. She received hydrocor...

ea0034p278 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

Therapeutic durability of the GLP1-based therapy Liraglutide in patients with type 2 diabetes mellitus

Border Daniel , Clayton Wendy , Thadani Puja , Reed Joseph , Randeva Harpal , Barber Thomas

Introduction: Therapeutic durability of GLP1-based therapies in patients with type 2 diabetes mellitus (T2D) is incompletely understood. Our aim was to explore the therapeutic effects of GLP1 based therapies in patients with T2D.Methods: This was a retrospective study on patients with T2D (n=55) who attend a specialist clinic at UHCW, Coventry, and who had been treated with the GLP1 based therapy, Liraglutide, for at least 6 months. A successful...